These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Proton magnetic resonance studies of bradykinin antagonists. Liu X; Stewart JM; Gera L; Kotovych G Biopolymers; 1993 Aug; 33(8):1237-47. PubMed ID: 8364157 [TBL] [Abstract][Full Text] [Related]
24. The importance of the N-terminal beta-turn in bradykinin antagonists. Miskolzie M; Gera L; Stewart JM; Kotovych G J Biomol Struct Dyn; 2000 Oct; 18(2):249-60. PubMed ID: 11089646 [TBL] [Abstract][Full Text] [Related]
25. Bradykinin stimulates glutamate uptake via both B1R and B2R activation in a human retinal pigment epithelial cells. Lim SK; Park MJ; Jung HK; Park AY; Kim DI; Kim JC; Bae CS; Kim KY; Yoon KC; Han HJ; Park SH Life Sci; 2008 Dec; 83(23-24):761-70. PubMed ID: 18948121 [TBL] [Abstract][Full Text] [Related]
26. SSR240612 [(2R)-2-[((3R)-3-(1,3-benzodioxol-5-yl)-3-[[(6-methoxy-2-naphthyl)sulfonyl]amino]propanoyl)amino]-3-(4-[[2R,6S)-2,6-dimethylpiperidinyl]methyl]phenyl)-N-isopropyl-N-methylpropanamide hydrochloride], a new nonpeptide antagonist of the bradykinin B1 receptor: biochemical and pharmacological characterization. Gougat J; Ferrari B; Sarran L; Planchenault C; Poncelet M; Maruani J; Alonso R; Cudennec A; Croci T; Guagnini F; Urban-Szabo K; Martinolle JP; Soubrié P; Finance O; Le Fur G J Pharmacol Exp Ther; 2004 May; 309(2):661-9. PubMed ID: 14747609 [TBL] [Abstract][Full Text] [Related]
27. Biotechnological Fluorescent Ligands of the Bradykinin B1 Receptor: Protein Ligands for a Peptide Receptor. Charest-Morin X; Marceau F PLoS One; 2016; 11(2):e0148246. PubMed ID: 26844555 [TBL] [Abstract][Full Text] [Related]
28. Bradykinin-related compounds as new drugs for cancer and inflammation. Stewart JM; Gera L; Chan DC; Bunn PA; York EJ; Simkeviciene V; Helfrich B Can J Physiol Pharmacol; 2002 Apr; 80(4):275-80. PubMed ID: 12025961 [TBL] [Abstract][Full Text] [Related]
29. A new class of pseudopeptide antagonists of the kinin B1 receptor containing alkyl spacers. Galoppini C; Meini S; Tancredi M; Di Fenza A; Triolo A; Quartara L; Maggi CA; Formaggio F; Toniolo C; Mazzucco S; Papini A; Rovero P J Med Chem; 1999 Feb; 42(3):409-14. PubMed ID: 9986712 [TBL] [Abstract][Full Text] [Related]
30. Switching of bradykinin-mediated nociception following partial sciatic nerve injury in mice. Rashid MH; Inoue M; Matsumoto M; Ueda H J Pharmacol Exp Ther; 2004 Mar; 308(3):1158-64. PubMed ID: 14634040 [TBL] [Abstract][Full Text] [Related]
31. Characterization of the B2 receptor and activity of bradykinin analogs in SHP-77 cell line by Cytosensor microphysiometer. Bironaite D; Gera L; Stewart JM Chem Biol Interact; 2004 Dec; 150(3):283-93. PubMed ID: 15560894 [TBL] [Abstract][Full Text] [Related]
32. Pharmacological profiles of the human and rabbit B1 receptors. Gobeil F; Neugebauer W; Nguyen-Le XK; Nea Allogho S; Pheng LH; Blouin D; Whalley ET; Regoli D Can J Physiol Pharmacol; 1997 Jun; 75(6):591-5. PubMed ID: 9276134 [TBL] [Abstract][Full Text] [Related]
33. New bradykinin analogues modified in the C-terminal part with sterically restricted 1-aminocyclohexane-1-carboxylic acid. Labudda-Dawidowska O; Wierzba TH; Prahl A; Kowalczyk W; Gawiński Ł; Plackova M; Slaninová J; Lammek B J Med Chem; 2005 Dec; 48(25):8055-9. PubMed ID: 16335929 [TBL] [Abstract][Full Text] [Related]
34. Radiolabeled R954 Derivatives for Imaging Bradykinin B1 Receptor Expression with Positron Emission Tomography. Kuo HT; Pan J; Lau J; Zhang C; Zeisler J; Colpo N; Bénard F; Lin KS Mol Pharm; 2017 Mar; 14(3):821-829. PubMed ID: 28094956 [TBL] [Abstract][Full Text] [Related]
35. N-terminal extended conjugates of the agonists and antagonists of both bradykinin receptor subtypes: structure-activity relationship, cell imaging using ligands conjugated with fluorophores and prospect for functionally active cargoes. Gera L; Roy C; Bawolak MT; Charest-Morin X; Marceau F Peptides; 2012 Apr; 34(2):433-46. PubMed ID: 22349904 [TBL] [Abstract][Full Text] [Related]
36. A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 1. Construction of the basic framework. Abe Y; Kayakiri H; Satoh S; Inoue T; Sawada Y; Imai K; Inamura N; Asano M; Hatori C; Katayama A; Oku T; Tanaka H J Med Chem; 1998 Feb; 41(4):564-78. PubMed ID: 9484506 [TBL] [Abstract][Full Text] [Related]
37. New bradykinin B(2) receptor antagonists - influence of C-terminal segment modifications on their pharmacological properties. Sleszyńska M; Kwiatkowska A; Sobolewski D; Wierzba TH; Katarzyńska J; Zabrocki J; Borovickova L; Slaninová J; Prahl A Acta Biochim Pol; 2009; 56(4):641-8. PubMed ID: 19997652 [TBL] [Abstract][Full Text] [Related]
38. MEN16132, a novel potent and selective nonpeptide kinin B2 receptor antagonist: in vivo activity on bradykinin-induced bronchoconstriction and nasal mucosa microvascular leakage in anesthetized guinea pigs. Valenti C; Cialdai C; Giuliani S; Lecci A; Tramontana M; Meini S; Quartara L; Maggi CA J Pharmacol Exp Ther; 2005 Nov; 315(2):616-23. PubMed ID: 16027229 [TBL] [Abstract][Full Text] [Related]
39. Requirement for direct cross-talk between B1 and B2 kinin receptors for the proliferation of androgen-insensitive prostate cancer PC3 cells. Barki-Harrington L; Bookout AL; Wang G; Lamb ME; Leeb-Lundberg LM; Daaka Y Biochem J; 2003 Apr; 371(Pt 2):581-7. PubMed ID: 12534343 [TBL] [Abstract][Full Text] [Related]
40. Fluorescent ligands of the bradykinin B1 receptors: pharmacologic characterization and application to the study of agonist-induced receptor translocation and cell surface receptor expression. Bawolak MT; Gera L; Morissette G; Bouthillier J; Stewart JM; Gobeil LA; Lodge R; Adam A; Marceau F J Pharmacol Exp Ther; 2009 Apr; 329(1):159-68. PubMed ID: 19136639 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]